JP7470161B2 - タクロリムスを含む徐放性薬剤学的製剤 - Google Patents
タクロリムスを含む徐放性薬剤学的製剤 Download PDFInfo
- Publication number
- JP7470161B2 JP7470161B2 JP2022135597A JP2022135597A JP7470161B2 JP 7470161 B2 JP7470161 B2 JP 7470161B2 JP 2022135597 A JP2022135597 A JP 2022135597A JP 2022135597 A JP2022135597 A JP 2022135597A JP 7470161 B2 JP7470161 B2 JP 7470161B2
- Authority
- JP
- Japan
- Prior art keywords
- tacrolimus
- sustained release
- disintegrant
- formulation
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title claims description 38
- 229960001967 tacrolimus Drugs 0.000 title claims description 36
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title claims description 33
- 238000013268 sustained release Methods 0.000 title claims description 28
- 239000012730 sustained-release form Substances 0.000 title claims description 28
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 239000007884 disintegrant Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 23
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 14
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 14
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000007962 solid dispersion Substances 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 10
- 238000007922 dissolution test Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- -1 alkali metal salt Chemical class 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241001647839 Streptomyces tsukubensis Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical class CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
Description
タクロリムスを含む徐放性製剤の調製
以下の調製方法に従い、タクロリムスを含む徐放性製剤を調製した。有機溶媒に、タクロリムス水和物、ヒドロキシプロピルメチルセルロース、エチルセルロース、乳糖、及びクロスカルメロースナトリウムを入れて顆粒を調製した後、乾燥させ、ふるいに通して固体分散体を調製した。調製した固体分散体、乳糖及びステアリン酸マグネシウムを均一に混合してから、ゼラチンカプセルに充填した。
溶解試験
実施例1~5のカプセルを用いて、以下の溶解試験条件に従って溶解試験を実施した。比較例として、アステラス製薬コリア製のADVAGRAF徐放性カプセル5mgを使用した。
1)溶解法:韓国薬局方の一般試験、溶解試験の第2法(パドル法)
2)試験溶液:希リン酸(3→50)でpH4.5に調整した0.07%SLSに0.005%ヒドロキシプロピルセルロース(分子量:約100,000)が含有されるように添加してから十分に撹拌した溶液、900mL
3)溶解温度:37.0±0.5℃
4)回転速度:50rpm
1)検出器:紫外吸光光度計(測定波長:205nm)
2)カラム:Merck-RP18(4.0×55mm、3μM)またはそれに相当するカラム
3)注入量:100μL
4)流量:1.2mL/min
5)カラム温度:60℃前後の一定温度
6)サンプル温度:10℃前後の一定温度
7)移動相:アセトニトリル、tert-ブチルメチルエーテル、及び6mMリン酸の混合液(430:50:520)
薬物動態(pharmacokinetics;PK)試験
実施例1及び比較例に対して、pK試験を実施した。
1)比較例:アステラス製薬コリア製ADVAGRAF徐放性カプセル5mg
2)被験者数:合計50人
3)試験デザイン:2×2交差試験
4)試験方法:被験者全員は、8時30分から20分以内に、900Kcal以上、脂肪35%以上に設計された高脂肪の朝食をとり、食事を開始してから30分が経過したときに150mLの水と共に試験薬を服用
5)採血ポイント:薬物投与直前、薬物を投与してから1、2、2.5、3、3.5、4、5、6、8、10、12、24、48、72、96、及び120時間後の合計17ポイント
6)分析対象:血中タクロリムス濃度の測定
次に、本発明の好ましい態様を示す。
1. 活性成分としての、タクロリムス、その薬剤学的に許容可能な塩、またはその水和物、及び崩壊剤を含む、徐放性薬剤学的製剤。
2. 前記崩壊剤が、製剤の総重量に対して、0.005~1.000重量%の範囲で含まれることを特徴とする、上記1に記載の徐放性薬剤学的製剤。
3. 前記崩壊剤が、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、クロスポビドン、及びデンプングリコール酸ナトリウムからなる群から1種以上選択されることを特徴とする、上記1に記載の徐放性薬剤学的製剤。
4. 前記崩壊剤が、クロスカルメロースナトリウムであることを特徴とする、上記3に記載の徐放性薬剤学的製剤。
5. 以下のステップを含み、タクロリムス、その薬剤学的に許容可能な塩、またはその水和物を活性成分として含む、徐放性薬剤学的製剤の調製方法:
-有機溶媒に、タクロリムス水和物、ヒドロキシプロピルメチルセルロース、エチルセルロース、乳糖、及びクロスカルメロースナトリウムを添加して、固体分散体を調製するステップ、及び
-調製した固体分散体、乳糖及びステアリン酸マグネシウムを混合するステップ。
6. 前記クロスカルメロースナトリウムが、製剤の総重量に対して、0.005~1.000重量%の範囲で含まれることを特徴とする、上記5に記載の徐放性薬剤学的製剤の調製方法。
Claims (2)
- 活性成分としての、タクロリムス、その薬剤学的に許容可能な塩、またはその水和物、崩壊剤、ヒドロキシプロピルメチルセルロース、及びエチルセルロースを含む、徐放性薬剤学的製剤であって、前記崩壊剤が、製剤の総重量に対して、0.02~0.5重量%の範囲で含まれるクロスカルメロースナトリウムであり、ヒドロキシプロピルメチルセルロース及びエチルセルロースの重量が同一である、前記徐放性薬剤学的製剤。
- タクロリムス、その薬剤学的に許容可能な塩、またはその水和物を活性成分として含む、徐放性薬剤学的製剤の調製方法であって、以下のステップを含み:
-有機溶媒に、タクロリムス水和物、ヒドロキシプロピルメチルセルロース、エチルセルロース、乳糖、及びクロスカルメロースナトリウムを添加して、固体分散体を調製するステップ、及び
-調製した固体分散体、乳糖及びステアリン酸マグネシウムを混合するステップ、
前記クロスカルメロースナトリウムが、製剤の総重量に対して、0.02~0.5重量%の範囲で含まれる、前記調製方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0071811 | 2018-06-22 | ||
KR1020180071811A KR102081176B1 (ko) | 2018-06-22 | 2018-06-22 | 타크로리무스를 포함하는 서방형 약제학적 제제 |
PCT/KR2019/007460 WO2019245309A1 (en) | 2018-06-22 | 2019-06-20 | A sustained release pharmaceutical preparation comprising tacrolimus |
JP2021518413A JP2021526559A (ja) | 2018-06-22 | 2019-06-20 | タクロリムスを含む徐放性薬剤学的製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518413A Division JP2021526559A (ja) | 2018-06-22 | 2019-06-20 | タクロリムスを含む徐放性薬剤学的製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022162149A JP2022162149A (ja) | 2022-10-21 |
JP7470161B2 true JP7470161B2 (ja) | 2024-04-17 |
Family
ID=68983011
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518413A Pending JP2021526559A (ja) | 2018-06-22 | 2019-06-20 | タクロリムスを含む徐放性薬剤学的製剤 |
JP2022135597A Active JP7470161B2 (ja) | 2018-06-22 | 2022-08-29 | タクロリムスを含む徐放性薬剤学的製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518413A Pending JP2021526559A (ja) | 2018-06-22 | 2019-06-20 | タクロリムスを含む徐放性薬剤学的製剤 |
Country Status (5)
Country | Link |
---|---|
JP (2) | JP2021526559A (ja) |
KR (1) | KR102081176B1 (ja) |
CN (1) | CN112351773A (ja) |
TW (1) | TWI762789B (ja) |
WO (1) | WO2019245309A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115944630B (zh) * | 2023-02-06 | 2024-04-05 | 华北制药股份有限公司 | 一种他克莫司缓释制剂及其制备方法 |
CN116159034B (zh) * | 2023-04-23 | 2023-07-04 | 国药集团川抗制药有限公司 | 一种他克莫司缓释胶囊及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999049863A1 (fr) * | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
WO2008041553A1 (fr) | 2006-09-26 | 2008-04-10 | Astellas Pharma Inc. | Préparation à libération entretenue de tacrolimus |
WO2008084698A1 (ja) * | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | タクロリムス徐放性医薬組成物 |
WO2010005980A1 (en) * | 2008-07-08 | 2010-01-14 | Lifecycle Pharma A/S | Tacrolimus for improved treatment of transplant patients |
CN108379235B (zh) * | 2018-06-01 | 2020-06-23 | 杭州中美华东制药有限公司 | 能够快速崩解的他克莫司缓释片剂组合物 |
-
2018
- 2018-06-22 KR KR1020180071811A patent/KR102081176B1/ko active IP Right Grant
-
2019
- 2019-06-20 JP JP2021518413A patent/JP2021526559A/ja active Pending
- 2019-06-20 CN CN201980038619.2A patent/CN112351773A/zh active Pending
- 2019-06-20 TW TW108121435A patent/TWI762789B/zh active
- 2019-06-20 WO PCT/KR2019/007460 patent/WO2019245309A1/en active Application Filing
-
2022
- 2022-08-29 JP JP2022135597A patent/JP7470161B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2022162149A (ja) | 2022-10-21 |
TW202015663A (zh) | 2020-05-01 |
WO2019245309A1 (en) | 2019-12-26 |
KR20200000038A (ko) | 2020-01-02 |
JP2021526559A (ja) | 2021-10-07 |
TWI762789B (zh) | 2022-05-01 |
KR102081176B1 (ko) | 2020-02-25 |
CN112351773A (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7470161B2 (ja) | タクロリムスを含む徐放性薬剤学的製剤 | |
ES2292819T3 (es) | Composiciones farmaceuticas que comprenden acido micofenolico o sal de micofenolato. | |
PT2193788E (pt) | Composições farmacêuticas compreendendo dióxido de silício coloidal | |
JP2020158510A (ja) | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの製剤 | |
CN116637076A (zh) | 包含sGC刺激剂的固体分散体 | |
JP5417662B2 (ja) | ネビラピンの徐放性製剤 | |
RU2672573C2 (ru) | Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин | |
US10660963B2 (en) | Pharmaceutical composition containing tacrolimus and preparation methods thereof | |
JPH09501150A (ja) | カプセル製剤 | |
US20090074869A1 (en) | Pharmaceutical formulations | |
KR20090086686A (ko) | 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법 | |
CN114126712A (zh) | 无定形司巴森坦(sparsentan)组合物 | |
RU2767872C2 (ru) | Фармацевтическая композиция и способ ее получения | |
CN111565714B (zh) | 包含依维莫司的实现稳定化的药剂学制剂 | |
CN112933049A (zh) | 含无定型态芳杂环化合物的组合物、其制备方法及用途 | |
KR20160054317A (ko) | 로베글리타존을 함유하는 경구 투여용 약제학적 조성물 | |
RU2248205C1 (ru) | Лекарственное средство в виде желатиновой капсулы | |
JPH01168619A (ja) | 新規な酢酸クロルマジノン固形製剤 | |
RU2247561C1 (ru) | Комбинированная фармацевтическая композиция с противотуберкулёзным действием | |
EP4268816A1 (en) | Oral solid preparation | |
KR20220088683A (ko) | 치다미드 제약 조성물, 이의 제조 방법 및 이의 용도 | |
JP2023532126A (ja) | パゾパニブを有効成分として含む錠剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231005 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240405 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7470161 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |